FDA Approves Silvergate's Oral Formulation of Hypertension Treatment

Tuesday, September 27, 2016

The Food and Drug Administration (FDA) has approved Epaned (enalapril maleate; Silvergate Pharmaceuticals) Oral Solution for the treatment of hypertension in adults and children >1 month, to lower blood pressure. It is also indicated to treat symptomatic heart failure and asymptomatic left ventricular dysfunction.

Epaned is already available as a Kit containing 150mg/150mLpowder for oral solution after reconstitution. The new Oral Solution has a 22 month expiry when stored refrigerated and a 60 day in-use period after dispensing, when stored at room temperature.

Full Story  
Continue Reading

ArcherDX dives into liquid biopsy research with Reveal ctDNA™ 28 assay

Thursday, September 22, 2016

(Boulder, CO) ArcherDX, the leader in NGS-based gene fusions, has announced the addition of a liquid biopsy assay to their portfolio. Archer® Reveal ctDNA™ 28 is the first in a line of Archer assays developed for liquid biopsy research applications. 

Pyxant Labs Commences Clinical Laboratory Testing Services

Tuesday, September 20, 2016

COLORADO SPRINGS, CO (PRWEB) SEPTEMBER 20, 2016 Pyxant Labs Inc., a privately held bioanalytical laboratory, today announced that its Clinical Laboratory Services (CLS) business unit is now operational and accepting clinical samples. Pyxant Labs CLS division assays patient specimens, including urine, oral fluids and blood, for prescribing physicians, clinics, and hospitals, supporting superior patient outcomes through medication management and clinical diagnostics. 

Venaxis Announces Acquisition of BiOptix

Wednesday, September 14, 2016

CASTLE ROCK, Colo., Sept. 13, 2016 /PRNewswire/ -- Venaxis®, Inc. (Nasdaq: APPY), announced today that it has acquired BiOptix Diagnostics, Inc., ("BiOptix") a Boulder, CO-based privately-held company. BiOptix has developed a proprietary Enhanced Surface Plasmon Resonance ("E‑SPR") technology platform for the detection of molecular interactions. The technology was developed in conjunction with Dr. John 'Jan' Hall, Adjoint Professor, JILA (University of Colorado), who shared the Nobel Prize for Physics in 2005. 

Colibri Heart Valve Enters Agreement with Venus Medtech to Form Joint Venture to Develop Next-Generation Transcatheter Heart Valve Technologies

Tuesday, September 13, 2016


Surefire Medical Reaches Critical Milestone in Germany

Monday, September 12, 2016

German Classification Code issued, allows for tracking and measuring use of Surefire devices  

Liver Cancer Treatment Using Surefire Technology Results in 92% Objective Response Rate

Saturday, September 10, 2016

Sept. 10, 2016—Barcelona, Spain—Surefire Medical, Inc. today announced at the Cardiovascular and Interventional Radiological Society of Europe Annual Scientific Congress the results of a multi-center registry in which the use of the Surefire Precision Infusion System to deliver therapy in the treatment of primary liver cancer (hepatocellularcarcinoma or HCC) was associated with a 68 percent complete tumor response and 92 percent objective tumor response. 

Blog: The Odd Juxtaposition in Biotech Venture Capital: Delivering Returns Amidst Sliding Market Share

Wednesday, September 07, 2016

Reposted from the Life Sci VC blog of Bruce Booth with Atlas Venture  

ArcherDX awards clinical research grants to medical investigators

Tuesday, September 06, 2016

BOULDER, CO – ArcherDX, Inc., the leader in NGS-based gene fusion detection, recently awarded grants to thirteen physician-scientists under the Archer® Research Challenge Grants program.